Cochlear Ltd (ASX: COH) shares have plunged into the red on Friday morning.
At the time of writing, the hearing solutions company’s shares are down 17.5% to $202.60.
This has been driven by the release of a softer-than-expected half-year result and an update on its earnings guidance for FY 2026.
Cochlear shares tumble on results
For the six months ended 31 December, Cochlear reported sales revenue of $1.176 billion, up just 1% on the prior corresponding period and down 2% in constant currency.
While cochlear implant units increased 6% to 27,016, revenue growth lagged unit growth due to mix, particularly a higher proportion of lower-priced emerging market units.
Gross margin declined two percentage points to 73%, reflecting a higher mix of lower-margin emerging market sales. Operating expenses rose 1% as the company continued investing in R&D and long-term growth initiatives.
This led to Cochlear’s underlying net profit falling 9% to $195 million, while statutory net profit dropped 21% to $161.5 million.
Despite this, the company’s board held its interim dividend steady at $2.15 per share, representing a 72% payout of underlying earnings.
Nexa rollout slower than hoped
A key factor weighing on Cochlear shares today appears to be the slower-than-expected rollout of the new Cochlear Nucleus Nexa system.
Management said the product registration and contract renewal process for the new implant took longer than anticipated, particularly where price increases were sought. While approvals in Europe, Asia Pacific and the US were secured mid-year, availability expanded progressively across the first half.
By December, around 80% of units sold comprised the new Nexa system, and management pointed to gains in market share late in the half. However, the delay meant only low single-digit revenue growth in developed markets during the period.
This timing issue appears to have disrupted the earnings trajectory investors were anticipating.
Outlook
Cochlear has reaffirmed its full-year underlying net profit guidance range of $435 million to $460 million.
However, it now expects earnings to land at the lower end of that range due to the first-half contracting delays.
There is also currency risk. Guidance assumes AUD/USD of 66 cents and AUD/EUR of 56 cents. If the Australian dollar remains at current levels, underlying net profit could be reduced by approximately $30 million.
The post Cochlear shares sink 17% on results day appeared first on The Motley Fool Australia.
Should you invest $1,000 in Cochlear Limited right now?
Before you buy Cochlear Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 Jan 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Cochlear posts modest sales growth but lower profit as Nexa launch continues
- 5 things to watch on the ASX 200 on Friday
- 5 ASX stocks that are still good value at over $100 a share
- I think these cheap ASX shares are strong buys this month
- Earnings preview: How do experts rate these blue-chip ASX stocks reporting this week?
Motley Fool contributor James Mickleboro has positions in Cochlear. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.